Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hector Tejeda-Mora has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Oncodevelopmental plasticity of the skeleton in myeloid neoplasms

    by Salim Atakhanov, Ian Ghezzi, Hector Tejeda Mora, Lucas Greven, Marta Rizk, Lina Schmidt, Katrin Goetz, Lina Merg, Valeria Solozobova, Adam Benabid, et al.

    Myelofibrosis in patients with myeloproliferative neoplasms (MPNs) is traditionally characterized by bone marrow fibrosis and osteosclerosis, with de novo bone formation commonly attributed to impaired osteoclast-mediated resorption. Here, we challenge this paradigm by demonstrating that a solitary clonal driver mutation simultaneously induces pathological bone formation and resorption, with osteosclerosis acting to conceal localized and active bone destruction rather than inhibiting it. Through population analysis; clinical imaging; patient-derived multi-tissue sequencing; murine models and organ-on-a-chip systems, we demonstrate that spatial and ontogeny-dependent remodeling in mesoderm- and neural crest–derived bones is mechanistically interconnected via a previously unidentified osteochondral stromal injury program. Neural crest–derived stromal cells suppress osteogenic programs and undergo injury-induced lineage plasticity with ectopic chondrogenesis, mirroring pathological remodeling in mesoderm-derived growth plate regions. This shared injury response promotes osteoclastogenesis and is mediated by a conserved Thrombospondin 1+ (THBS1+) stromal population that links fibrotic remodeling to bone loss. Combined pharmacological inhibition of THBS1 and JAK signaling reduces myeloproliferation, halts fibrosis progression, and restores two developmentally distinct bones, establishing THBS1 as a unifying therapeutic target in myelofibrosis.

  • Open Access

    Tissue-resident memory T cells in human kidney transplants have alloreactive potential

    by Daphne M. Hullegie-Peelen, Hector Tejeda-Mora, Marjolein Dieterich, Sebastiaan Heidt, Eric M.J. Bindels, Martin J. Hoogduijn, Dennis A. Hesselink, Carla C. Baan


  • Endothelial Cell Replacement of Human Veins, Modeling Vascular Repair and Endothelial Cell Chimerism

    by Hector Tejeda-Mora, Yvette Den Hartog, Ivo J. Schurink, Monique M.A. Verstegen, Jeroen de Jonge, Martijn W.F. van Den Hoogen, Carla C. Baan, Robert C. Minnee, Martin J. Hoogduijn, Luc J.W. van der Laan, et al.

    Allogeneic transplant organs are potentially highly immunogeneic. The endothelial cells (EC) located within the vascular system serve as the primary interface between the recipient’s immune system and the donor organ, playing a key role in the allo-immune response. In this study, we investigated the potential use of recipient-derived ECs in a vein recellularization model. Here, human iliac veins underwent complete decellularization using a triton X-100 protocol. We demonstrated the feasibility of re-endothelializing acellular blood vessels using either HUVEC or human venous-derived ECs, with this re-endothelization being sustainable for up to 28 days in vitro. The re-endothelialized veins exhibited the restoration of vascular barrier function, along with the restoration of innate immune regulatory capabilities, evident through the facilitation of monocytic cell transmigration and their polarization towards a macrophage phenotype following trans-endothelial extravasation. Finally, we explored whether recellularization with EC of a different donor could prevent antibody-mediated rejection. We demonstrated that in chimeric vessels, allogeneic EC became a target of the humoral anti-donor response after activation of the classical immune complement pathway whereas autologous EC were spared, emphasizing their potential utility prior to transplantation. In conclusion, our study demonstrates that replacement of EC in transplants could reduce the immunological challenges associated with allogeneic grafts.


  • Open Access

    Bio-distribution and longevity of mesenchymal stromal cell derived membrane particles

    by J. Vos, H. Tejeda-Mora, A. Merino, L. Wu, W.W. Woud, J.A.A. Demmers, W.F.J. van Ijcken, M.E.J. Reinders, M.J. Hoogduijn


  • Open Access

    Proteomic Analysis of Mesenchymal Stromal Cell-Derived Extracellular Vesicles and Reconstructed Membrane Particles

    by Hector Tejeda-Mora, Leticia G. Leon, Jeroen Demmers, Carla C. Baan, Marlies E. J. Reinders, Bertram Bleck, Eleuterio Lombardo, Ana Merino, Martin J. Hoogduijn

    Extracellular vesicles (EV) derived from mesenchymal stromal cells (MSC) are a potential therapy for immunological and degenerative diseases. However, large-scale production of EV free from contamination by soluble proteins is a major challenge. The generation of particles from isolated membranes of MSC, membrane particles (MP), may be an alternative to EV. In the present study we generated MP from the membranes of lysed MSC after removal of the nuclei. The yield of MP per MSC was 1 × 105 times higher than EV derived from the same number of MSC. To compare the proteome of MP and EV, proteomic analysis of MP and EV was performed. MP contained over 20 times more proteins than EV. The proteins present in MP evidenced a multi-organelle origin of MP. The projected function of the proteins in EV and MP was very different. Whilst proteins in EV mainly play a role in extracellular matrix organization, proteins in MP were interconnected in diverse molecular pathways, including protein synthesis and degradation pathways and demonstrated enzymatic activity. Treatment of MSC with IFNγ led to a profound effect on the protein make up of EV and MP, demonstrating the possibility to modify the phenotype of EV and MP through modification of parent MSC. These results demonstrate that MP are an attractive alternative to EV for the development of potential therapies. Functional studies will have to demonstrate therapeutic efficacy of MP in preclinical disease models.


  • Open Access

    Circulating endothelial cells transiently increase in peripheral blood after kidney transplantation

    by H. Tejeda-Mora, J. G. H. P. Verhoeven, W. Verschoor, K. Boer, D. A. Hesselink, M. W. F. van Den Hoogen, L. J. W. van der Laan, C. C. Baan, R. C. Minnee, M. J. Hoogduijn

    The diagnosis of kidney allograft rejection is based on late histological and clinical markers. Early, specific and minimally-invasive biomarkers may improve rejection diagnosis. Endothelial cells (EC) are one of the earliest targets in kidney transplant rejection. We investigated whether circulating EC (cEC) could serve as an earlier and less invasive biomarker for allograft rejection. Blood was collected from a cohort of 51 kidney transplant recipients before and at multiple timepoints after transplantation, including during a for cause biopsy. The number and phenotype of EC was assessed by flow-cytometric analysis. Unbiased selection of EC was done using principal component (PCA) analysis. Paired analysis revealed a transient cEC increase of 2.1-fold on the third day post-transplant, recovering to preoperative levels at seventh day post-transplant and onwards. Analysis of HLA subtype demonstrated that cEC mainly originate from the recipient. cEC levels were not associated with allograft rejection, allograft function or other allograft pathologies. However, cEC in patients with allograft rejection and increased levels of cEC showed elevated levels of KIM-1 (kidney injury marker-1). These findings indicate that cEC numbers and phenotype are affected after kidney transplantation but may not improve rejection diagnosis.


  • Metabolic engineering of a carbapenem antibiotic synthesis pathway in Escherichia coli

    by Helena Shomar, Sophie Gontier, Niels J. F. van Den Broek, Héctor Tejeda Mora, Marek J. Noga, Peter-Leon Hagedoorn, Gregory Bokinsky

    Carbapenems, a family of β-lactam antibiotics, are among the most powerful bactericidal compounds in clinical use. However, as rational engineering of native carbapenem-producing microbes is not currently possible, the present carbapenem supply relies upon total chemical synthesis of artificial carbapenem derivatives. To enable access to the full diversity of natural carbapenems, we have engineered production of a simple carbapenem antibiotic within Escherichia coli. By increasing concentrations of precursor metabolites and identifying a reducing cofactor of a bottleneck enzyme, we improved productivity by 60-fold over the minimal pathway and surpassed reported titers obtained from carbapenem-producing Streptomyces species. We stabilized E. coli metabolism against antibacterial effects of the carbapenem product by artificially inhibiting membrane synthesis, which further increased antibiotic productivity. As all known naturally occurring carbapenems are derived from a common intermediate, our engineered strain provides a platform for biosynthesis of tailored carbapenem derivatives in a genetically tractable and fast-growing species.